The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension.
This study sought to determine if metoprolol succinate ER (MET), and nebivolol (NEB), a β1-AR with increased bioavailability of nitric oxide (NO), would have differing effects on plasma asymmetric dimethylarginine concentration in hypertensives. It was hypothesized that NEB, a β1-AR antagonist and β3-AR agonist with NO-releasing properties, and MET, only a β1-AR antagonist, would have different effects on plasma asymmetric dimethylarginine (ADMA) concentration. Forty-one hypertensive subjects randomly received either 50 mg of MET (n = 19) or 5 mg of NEB (n = 22) for 4 weeks followed by 100 mg MET and 10 mg NEB for 4 weeks. ADMA and insulin-like growth factor-1 (IGF-1) were measured by enzyme-linked immunosorbent assay kit; endothelial progenitor cells were estimated using fluorescein-labeled monoclonal antibody to KDR and CD133 receptors; arterial augmentation index was measured by radial tonometry. Baseline systolic/diastolic blood pressure was 155.1 ± 18.7/85.3 ± 12.5 mm Hg for MET subjects and 157.6 ± 20.7/87.1 ± 14.0 mm Hg for NEB subjects. Baseline ADMA was 0.32 ± 0.123 μmol/L in the MET group and 0.4035 ± 0.1378 in the NEB group. ADMA increased 44.78% and 72% in the MET group at weeks 4 and 8 (P < .05 for both), respectively, without increase in the NEB group. At week 8, augmentation index was increased in the MET group (P < .05). IGF-1 and endothelial progenitor cells were unchanged by treatment. Plasma ADMA and augmentation index are increased in a dose-dependent fashion by MET but not with NEB.
Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA.
Ramprasad
R
Kandavar
Yusuke
Y
Higashi
Wei
W
Chen
Christopher
C
Blackstock
Charlotte
C
Vaughn
Sergiy
S
Sukhanov
Gary E
GE
Sander
Louise E
LE
Roffidal
Patrice
P
Delafontaine
Thomas D
TD
Giles
D000284:Administration, Oral; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001120:Arginine / Q000031:analogs & derivatives* / Q000378:metabolism; D001578:Benzopyrans / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001794:Blood Pressure / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D008875:Middle Aged; D000068577:Nebivolol; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol; C018524:N,N-dimethylarginine; D007334:Insulin-Like Growth Factor I; D001120:Arginine; D019001:Nitric Oxide Synthase; D008790:Metoprolol
Pharmacol Res. 2007 Dec;56(6):515-21
17977009
Curr Biol. 1999 Jul 29-Aug 12;9(15):845-8
10469573
Stroke. 2006 Aug;37(8):2024-9
16809568
Anadolu Kardiyol Derg. 2007 Dec;7(4):383-7
18065333
J Am Coll Cardiol. 2007 Feb 20;49(7):741-52
17306702
Ther Adv Cardiovasc Dis. 2008 Feb;2(1):25-35
19124405
Circulation. 2009 Mar 31;119(12):1592-600
19289633
Cardiovasc Ther. 2008 Summer;26(2):115-34
18485134
Br J Pharmacol. 1994 May;112(1):43-8
7518309
Vasc Med. 2005 Jul;10 Suppl 1:S45-8
16444868
Hypertension. 2007 Mar;49(3):563-8
17242303
Br J Pharmacol. 2009 Sep;158(1):300-13
19719783
Pharmacol Res. 2007 Apr;55(4):303-9
17280840
Am J Hypertens. 2007 Jul;20(7):777-83
17586413
J Am Coll Cardiol. 2009 Apr 28;53(17):1532-8
19389564
J Hypertens. 2007 Jan;25(1):127-32
17143183
J Clin Endocrinol Metab. 2007 Nov;92(11):4172-9
17726074
Lancet. 1992 Mar 7;339(8793):572-5
1347093
Am J Hypertens. 2008 Nov;21(11):1251-7
18772860